Short-Term Rationing of Combination Antiretroviral Therapy: Impact on Morbidity, Mortality, and Loss to Follow-Up in a Large HIV Treatment Program in Western Kenya

Table 1

Enrollment sociodemographics and clinic characteristics of the comparison groups.

Variable	Pre-cap group (𝑛=4714), 𝑛 (%)	Cap group (𝑛=4295), 𝑛 (%)	P value
Sex
Male	1849 (39.2)	1741 (40.5)	0.212
Female	2865 (60.8)	2554 (59.5)
Missing	0 (0)	0 (0)
Age^a
Median	37.0	36.9	0.255
IQR	31.0–44.1	30.6–44.0
Missing	0 (0)	0 (0)
Clinic location^a
Urban	2315 (49.1)	2176 (50.7)	0.146
Rural	2399 (50.9)	2119 (49.3)
Missing	0 (0)	0 (0)
Travel time to clinic^a
<30 minutes	1093 (23.4)	962 (23.1)	0.100
30–60 minutes	1467 (31.5)	1400 (33.6)
1-2 hours	1266 (27.2)	1127 (27.0)
>2 hours	836 (17.9)	683 (16.4)
Missing	52 (1.1)	123 (2.9)
WHO clinical stage^a
I	637 (15.1)	533 (14.5)	0.780
II	839 (19.8)	754 (20.6)
III	2278 (53.9)	1977 (54.0)
IV	476 (11.3)	400 (10.9)
Missing	484 (10.3)	631 (14.7)
CD4^a
Median	99.0	94.0	0.081
IQR	41.0–163	38.0–161
Missing	59 (1.3)	49 (1.1)
Use of Cotrimoxazole or Dapsone
Yes	3851 (81.7)	3282 (76.4)	<0.001
No	863 (18.3)	1013 (23.6)
Missing	0 (0)	0 (0)
TB treatment^a
Yes	1180 (25.0)	1121 (26.1)	0.246
No	3534 (75.0)	3174 (73.9)
Missing	0 (0)	0 (0)

^aAt Enrollment.